• 제목/요약/키워드: liver cancer

검색결과 1,670건 처리시간 0.027초

Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy

  • Alkhatib, Alzhraa;Gomaa, Asmaa;Allam, Naglaa;Rewisha, Eman;Waked, Imam
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권16호
    • /
    • pp.6929-6934
    • /
    • 2015
  • Background: Real life management of hepatocellular carcinoma occasionally deviates from guidelines for recommended therapy. Aims: To evaluate how frequent this deviation happens in our center and assess its impact on outcome. Materials and Methods: The treatment of 770 patients (87% males, mean age 57.8 years) was analyzed and the effect of deviation on outcome over 36 months was examined. Results: Of Barcelona Clinic liver cancer stages 0 and A patients, 65.8% received resection, ablation, liver transplantation or transarterial chemoembolisation for unresectable tumors more than 5 cm in diameter, and 34.2% received treatment recommended for later stages. Of stage B patients, 62.2% received recommended therapy, 34.3% of patients received supportive therapy or sorafenib and 3.5% received upward treatment stage migration. Among stage C patients, 7.6% received sorafenib, and most (79.2%) were given supportive care. Deviation from recommended therapy occurred in 34.2%, 37.7%, and 92.4% in stages 0-A, B and C. Survival of stage 0-A patients who received downwards treatment stage migration was lower than those who received recommended treatment (p <0.001). Upward treatment stage migration in stages B, C and D did not improve survival compared to those who received recommended treatment. Conclusions: Deviation from recommended therapy had a negative impact on survival in Barcelona Clinic liver cancer stage A patients.

Endoplasmic Reticulum Stress Induces CAP2 Expression Promoting Epithelial-Mesenchymal Transition in Liver Cancer Cells

  • Yoon, Sarah;Shin, Boram;Woo, Hyun Goo
    • Molecules and Cells
    • /
    • 제44권8호
    • /
    • pp.569-579
    • /
    • 2021
  • Cyclase-associated protein 2 (CAP2) has been addressed as a candidate biomarker in various cancer types. Previously, we have shown that CAP2 is expressed during multi-step hepatocarcinogenesis; however, its underlying mechanisms in liver cancer cells are not fully elucidated yet. Here, we demonstrated that endoplasmic reticulum (ER) stress induced CAP2 expression, and which promoted migration and invasion of liver cancer cells. We also found that the ER stress-induced CAP2 expression is mediated through activation of protein kinase C epsilon (PKCε) and the promotor binding of activating transcription factor 2 (ATF2). In addition, we further demonstrated that CAP2 expression promoted epithelial-mesenchymal transition (EMT) through activation of Rac1 and ERK. In conclusion, we suggest that ER stress induces CAP2 expression promoting EMT in liver cancer cells. Our results shed light on the novel functions of CAP2 in the metastatic process of liver cancer cells.

Potential Therapeutic Efficacy of Curcumin in Liver Cancer

  • Dai, Xin-Zheng;Yin, Hai-Tao;Sun, Ling-Fei;Hu, Xiang;Zhou, Chong;Zhou, Yun;Zhang, Wei;Huang, Xin-En;Li, Xiang-Cheng
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권6호
    • /
    • pp.3855-3859
    • /
    • 2013
  • Purpose: Liver cancer, one of the most common cancers in China, is reported to feature relatively high morbidity and mortality. Curcumin (Cum) is considered as a drug possessing anti-angiogenic, anti-inflammation and anti-oxidation effect. Previous research has demonstrated antitumor effects in a series of cancers. Materials and Methods: In this study the in vitro cytotoxicity of Cum was measured by MTT assay and pro-apoptotic effects were assessed by DAPI staining and measurement of caspase-3 activity. In vivo anti-hepatoma efficacy of Cum was assessed with HepG2 xenografts. Results: It is found that Cum dose-dependently inhibited cell growth in HepG2 cells with activation of apoptosis. Moreover, Cum delayed the growth of liver cancer in a dose-dependent manner in nude mice. Conclusions: Cum might be a promising phytomedicine in cancer therapy and further efforts are needed to explore this therapeutic strategy.

질병예방행위 분석을 통한 확률적 인간생명가치 추정: 암 검진 행위 분석을 중심으로 (Estimating the Value of Statistical Life by Analysing Disease Protective Behavior: Focusing on Medical Examination of Cancer)

  • 신영철
    • 자원ㆍ환경경제연구
    • /
    • 제17권4호
    • /
    • pp.845-873
    • /
    • 2008
  • 이 연구에서는 회피행위의 다목적성(결합생산) 문제를 최소화할 수 있는 암 검진 행위라는 회피행위 자료에 대해 표본선택편의를 극복할 수 있는 모형을 적용하여, 사망위험 감소에 대한 지불의사금액의 도출과 더불어 확률적 인간생명가치(value of statistical life : VSL)를 추정하였다. 간암 사망위험을 감소시키기 위한 비용 및 시간 등과 관련된 자료를 이용하여 건강 및 안전에 대한 가계생산함수모형의 틀에서 사망위험 감소를 위한 한계편익을 추정하였다. 간암 검사를 받을 확률을 높아지도록 하는 변수는 남성인 경우, 연령이 많을수록, 교육받은 기간이 길수록, 유배우자인 경우, 현재 흡연자인 경우, 가구소득이 높을수록, 건강염려 정도가 높을 때인 것으로 나타났다. 간암 검진과 관련된 비용은 조기 검진으로 인하여 감소하는 사망위험의 크기 및 성별, 교육받은 기간, 유배우자 여부, 가구 소득에 의해서도 예상한 대로 유의한 영향을 받았다. 암 검진에 의한 사망위험 감소 크기(risk)의 한계효과는 321,097원이다. 교육년수(edu)의 경우 1년 증가하면 간암 검진비용이 905원, 가구 소득(hinc)이 100만 원 증가하면 간암 검진비용이 1,743원 증가한다. 한편 남성인 경우가 여성에 비해 간암 검진비용으로 12,310원을, 유배우자가 무배우자에 비해 7,969원을 더 부담하고 있다. 암 검진으로 인한 조기사망위험 감소로부터 도출된 확률적 인간생명가치는 평균 사망위험 감소 수준 및 평균 암 검진 비용 수준에서 3억 2,110만 원이다. 또한 암 검진 소요비용과 암 검진 효과에 대한 불확실성을 위해 민감도 분석의 결과에서는 확률적 인간생명가치가 1억 6,055만 원~6억 4,219만 원으로 추정되었다.

  • PDF

암치료를 위한 네트워크 기반 접근방식 활용 시스템 수준 연구 (Investigating herbal active ingredients and systems-level mechanisms on the human cancers)

  • 이원융
    • 대한한의학방제학회지
    • /
    • 제30권3호
    • /
    • pp.175-182
    • /
    • 2022
  • Objective : This study aims to investigate the active ingredients and potential mechanisms of the beneficial herb on human cancers such as the liver by employing network pharmacology. Methods : Ingredients and their target information was obtained from various databases such as TM-MC, TTD, and Drugbank. Related protein for liver cancer was retrieved from the Comparative Toxicogenomics Database and literature. A hypergeometric test and gene set enrichment analysis were conducted to evaluate associations between protein targets of red ginseng (Panax ginseng C. A. Meyer) and liver cancer-related proteins and identify related signaling pathways, respectively. Network proximity was employed to identify active ingredients of red ginseng on liver cancer. Results : A compound-target network of red ginseng was constructed, which consisted of 363 edges between 53 ingredients and 121 protein targets. MAPK signaling pathway, PI3K-Akt signaling pathway, p53 signaling pathway, TGF-beta signaling pathway, and cell cycle pathway was significantly associated with protein targets of red ginseng. Network proximity results indicated that Ginsenoside Rg1, Acetic Acid, Ginsenoside Rh2, 20(R)-Ginsenoside Rg3, Notoginsenoside R1, Ginsenoside Rk1, 2-Methylfuran, Hexanal, Ginsenoside Rd, Ginsenoside Rh1 could be active ingredients of red ginseng against liver cancer. Conclusion : This study suggests that network-based approaches could be useful to explore potential mechanisms and active ingredients of red ginseng for liver cancer.

Altered lipid metabolism as a predisposing factor for liver metastasis in MASLD

  • So Jung Kim;Jeongeun Hyun
    • Molecules and Cells
    • /
    • 제47권2호
    • /
    • pp.100010.1-100010.12
    • /
    • 2024
  • Recently, the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing due to the high prevalence of metabolic conditions, such as obesity and type 2 diabetes mellitus. Steatotic liver is a hotspot for cancer metastasis in MASLD. Altered lipid metabolism, a hallmark of MASLD, remodels the tissue microenvironment, making it conducive to the growth of metastatic liver cancer. Tumors exacerbate the dysregulation of hepatic metabolism by releasing extracellular vesicles and particles into the liver. Altered lipid metabolism influences the proliferation, differentiation, and functions of immune cells, contributing to the formation of an immunosuppressive and metastasis-prone liver microenvironment in MASLD. This review discusses the mechanisms by which the steatotic liver promotes liver metastasis progression, focusing on its role in fostering an immunosuppressive microenvironment in MASLD. Furthermore, this review highlights lipid metabolism manipulation strategies for the therapeutic management of metastatic liver cancer.

간암 줄기세포의 기원 (Cellular origin of liver cancer stem cells)

  • 은종렬
    • Journal of Yeungnam Medical Science
    • /
    • 제32권1호
    • /
    • pp.1-7
    • /
    • 2015
  • Over several decades, a hierarchical cancer stem cell (CSC) model has been established in development of solid cancers, including hepatocellular carcinoma(HCC). In terms of this concept, HCCs originate from liver CSCs. Clinically HCCs show a wide range of manifestations from slow growth to very aggressive metastasis. One of the reasons may be that liver CSCs originate from different cells. This review describes the basic concept of CSCs and the cellular origin of liver CSCs.

Insulin receptor substrate 2: a bridge between Hippo and AKT pathways

  • Jeong, Sun-Hye;Lim, Dae-Sik
    • BMB Reports
    • /
    • 제51권5호
    • /
    • pp.209-210
    • /
    • 2018
  • NAFLD induces the development of advanced liver diseases such as NASH and liver cancer. Therefore, understanding the mechanism of NAFLD development is critical for its prevention and treatment. Ablation of PTEN or Hippo pathway components induces liver cancer in a murine model by hyperactive AKT or YAP/TAZ, respectively. Although the regulation of these two pathways occurs in the same hepatocyte, the details of crosstalk between Hippo-YAP/TAZ and PTEN-AKT pathways in liver homeostasis and tumorigenesis still remain unclear. Here, we found that depletion of both PTEN and SAV1 in liver promotes spontaneous NAFLD and liver cancer through hyperactive AKT via YAP/TAZ-mediated up-regulation of IRS2 transcription. Conversely, NAFLD is rescued by both ablation of YAP/TAZ and activation of the Hippo pathway. Furthermore, human HCC patients with NAFLD showed strong correlation between YAP/TAZ and IRS2 or phospho-AKT expression. Finally, the inhibition of AKT by MK-2206 treatment attenuates NAFLD development and tumorigenesis. Our findings indicate that Hippo pathway interacts with AKT signaling during the intervention with IRS2 to prevent NAFLD and liver cancer.

Diagnostic Value of Fecal Calprotectin as a Screening Biomarker for Gastrointestinal Malignancies

  • Khoshbaten, Manouchehr;Pishahang, Parinaz;Nouri, Mohammad;Lashkari, Alireza;Alizadeh, Mahasti;Rostami-Nejad, Mohammad
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권4호
    • /
    • pp.1667-1670
    • /
    • 2014
  • Background: Calprotectin in feces seems to be a more sensitive marker for gastrointestinal (GI) cancers than fecal occult blood, but its specificity may be too low for screening average risk populations. This study aims at evaluating the diagnostic value of fecal calprotectin as a screening biomarker for GI malignancies. Materials and Methods: In a case-control study, 100 patients with GI malignancies (50 patients with colorectal cancer and 50 patients with gastric cancer) and 50 controls were recruited in Tabriz Imam Reza and Sina hospitals during a 24-month period. One to two weeks after the last endoscopy/colonoscopy, fecal specimens were collected by the patients and examined by ELISA method for quantitative measurement of calprotectin content. The results were compared between the three groups. Results: The mean fecal calprotectin level was $109.1{\pm}105.3$ (2.3-454.3, median:74), $241.1{\pm}205.2$ (3.4-610.0, median:19.3) and $45.9{\pm}55.1{\mu}g/g$ (1.3-257.1, median:19.3) in gastric cancer, colorectal cancer and control group, respectively, the differences being significant (p<0.001) and remaining after adjustment for age. The optimal cut-off point for fecal calprotectin was ${\geq}75.8{\mu}g/g$ for distinguishing colorectal cancer from normal cases (sensitivity and specificity of 80% and 84%, respectively). This value was ${\geq}41.9{\mu}g/g$ for distinguishing gastric cancer from normal cases (sensitivity and specificity of 62%). Conclusions: Our results revealed that fecal calprotectin might be a useful and non-invasive biomarker for distinguishing colorectal cancer from non-malignant GI conditions. However, due to low sensitivity and specificity, this biomarker may not help physicians distinguishing gastric cancer cases from healthy subjects.